Improving the ACS Triage—Using High Sensitivity TroponinI and Copeptin for Early ‘Rule-Out’ of AMI

Kankra, Mamta; Mehta, Ashwani; Sawhney, J.P.S.; Solanki, Sanket; Bhargava, S.; Ahirwar, Ashok Kumar; Manocha, Anjali; Singla, Priyanka; Sharma, Ajay; Sharma, Manish

doi:10.1007/s12291-021-01015-7

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased serum levels of copeptin are detectable in patients with AMI at presentation to the ED, already in the first minutes after AMI onset. 10 In the BIC-8 trial, a dual biomarker strategy based on determination of copeptin and hs-cTnT at presentation was as efficient as the standard strategy based on serial cTn to predict major adverse cardiac events (MACE) at 30 days (4.34% vs. 4.27%), suggesting that copeptin combined with cTn at presentation may replace the serial determination of cTn with retesting at 3 hours or later, as recommended by the standard protocol today. 11 Elseidy et al also reported that negative copeptin combined with negative hs-cTn testing in patients at low-tointermediate risk of ACS may allow a rapid and safe discharge from the ED, effectively ruling out the non-STEMI type of ACSs.…”

Section: Alternative Biomarkers Of Myocardial Injurymentioning

confidence: 99%

Cardiac Biomarkers in 2022 – a Vital Tool for Emergency Care

Benedek

Marton-Popovici

2022

Journal of Cardiovascular Emergencies

View full text Add to dashboard Cite

The role of cardiac biomarkers in diagnosing acute myocardial infarction is undoubted. In the 2020 guidelines of the European Society of Cardiology, the measurement of cardiac peptides to gain prognostic information has a class IIa indication in all patients with ACS. In emergency care, ruling out a non-ST elevation myocardial infarction requires documentation of normal levels of cardiac biomarkers, which remain stable or have very small variations within several hours. This review aims to summarize the current knowledge and recent progresses in the field of cardiac biomarker discovery, from their routine use in emergency rooms to their prognostic roles in modern risk assessment tools. Integrated approaches combining cardiac troponin with other biomarkers of ventricular dysfunction or inflammation, or with modern cardiac imaging in emergency care are also presented, as well as the role of modern algorithms for serial troponin measurement in the modern management of emergency departments.

show abstract

Section: Alternative Biomarkers Of Myocardial Injurymentioning

confidence: 99%